Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®

NCT03201770 is registered in ClinicalTrials.gov with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT03201770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03201770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd.
Phase
Phase 4
Overall status
Completed
Start date
June 22, 2017
Completion date
April 10, 2019
Enrollment
8,572 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malaria,falciparum